Skip to content
Deals

Omega-3 (DHA and EPA) and blood triglycerides: grade A

Strong evidence. Direction: Benefit.

A Strong

Educational guidance, not medical advice

Why this grade

Rubric condition met: >=1 meta-analysis (Cochrane, 86 RCTs) with consistent, dose-dependent direction, high-certainty evidence, at doses legally available

The 2020 Cochrane review (86 RCTs, 162,796 participants, MRC-funded) found that increasing long-chain omega-3 reduced triglycerides by about 15% in a dose-dependent way, graded high-certainty. Trial populations were adults at varying cardiovascular risk rather than only healthy adults. UK and Canadian regulators accept triglyceride claims at 2 g and 1-5 g EPA and DHA a day respectively.

How we grade evidence

Studies this grade rests on

Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.

Abdelhamid AS, Brown TJ, Brainard JS. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease Cochrane Database Syst Rev, 2020. PMID 32114706

Result not recorded
Design
Cochrane systematic review and meta-analysis of 86 RCTs (at least 12 months)
Sample
n = 162,796
Population
Adults at varying cardiovascular risk, mainly in high-income countries
Funding
Medical Research Council MR/K02325X/1 (PubMed grant list)

Search and history

Search (): (omega-3[ti] OR "omega 3"[ti]) AND cardiovascular[ti] AND "Cochrane Database Syst Rev"[ta]

  • Graded A (proposed): Proposed in the monograph draft
  • A to A (approved): Editor sign-off November 13, 2026: grade matches the editor-approved final page